FAT jabs have turned the tide on the obesity epidemic, but there’s a new challenge on the horizon – an obesity bounceback.

Pricey prescriptions and nagging medical costs are swamping some insurers and employers now. Patients may start paying for it ...

As GLP-1 adoption grows and new applications for the drugs come to light, experts say that could have sweeping impacts for ...

Novo Nordisk said on Monday it is offering its diabetes drug Ozempic for $499 per month to eligible cash-paying type 2 ...

Serena Williams recently shared that she started taking the GLP-1 drug Zepbound after having her two children. The tennis ...

With millions of Americans prescribed GLP-1 drugs, researchers warn of catastrophic risks ignored by Big Pharma.

About 12% of all U.S. adults have already tried using GLP-1 agonist drugs to control their weight, according to a survey ...

Drugmaker Novo Nordisk received accelerated approval for the drug’s use in people with moderate to advanced liver scarring, ...

Burke Wealth Management, an investment management company, released its “Focused Growth Strategy” second-quarter 2025 ...

Wegovy is now approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis.

Millions of Americans who have dropped pounds and boosted their health using popular obesity drugs like Wegovy are facing a ...

The approval makes Wegovy the only GLP-1 therapy cleared to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis. About 14.9 million U.S.